Drug intelligence / Profile preview

ICT-69

Development stage: Discontinued
Lead developer: EOM Pharmaceutical
Modality: Antibody-Based Therapeutics
Administration: Intravenous

Overview

ICT-69 is a murine monoclonal antibody developed by ImmunoCellular Therapeutics that targets an antigen expressed on human multiple myeloma and ovarian cancer cells, intended for use as an antineoplastic immunotherapy.[13][15] It was part of ImmunoCellular’s antibody pipeline alongside the glioblastoma vaccine ICT-107, with intellectual property covering its use in diagnosis and treatment of ovarian cancer and multiple myeloma, but it has not progressed into late-stage clinical development and appears to have been deprioritized in favor of other programs.[13][15]

Targets

SDC1 (Syndecan-1)

Beyond the preview

Go deeper on ICT-69.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ICT-69.

Explore the full profile